Testing GI-102 with and without pembrolizumab before surgery for a returning grade 4 brain tumor
Original title: GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a new immune drug, given before surgery, for a grade 4 brain tumor that has come back or is growing.
Who this trial is for. This trial is for people with IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary wildtype glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary or IDH mutated grade 4 astrocytoma. The tumor has come back after a time of improvement, or it is growing and getting worse. Some people get GI-102 by itself. Others get GI-102 along with pembrolizumab. Both are given before surgery.
Where it stands. This trial has not reported results. It is looking at whether this treatment is safe, easy to tolerate, and helpful before surgery. GI-102 is a bispecific fusion protein. It may change how the immune system works. It may also make it harder for tumor cells to grow and spread. Pembrolizumab may help the immune system attack the tumor. Whether either one helps people live better or longer is not known yet.
What this means, and what it doesn't
What it could mean: Treatment before surgery is already used to shrink a tumor and make it easier to remove. This trial asks if adding GI-102 to that step helps. If your tumor has come back or is growing, you might fit what this trial is studying. You could ask your care team about it. They can tell you if a trial like this makes sense for you.
What it doesn't mean: This does not mean GI-102 works. A trial is a test, not a proven treatment. Joining one is not a guarantee that you will be helped. You could get side effects, and the drug may not help your tumor at all. This is not a promise of a cure. It is also not a promise of a spot in the trial. The trial team decides who can join.
Source: ClinicalTrials.gov, October 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.